🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Preparation and protocol matters! In collaboration with Leon Kiriaev and Cory Baumann, we discuss how preparations and protocols impact strength loss induced by eccentric contractions in dystrophin-deficient skeletal muscle in Journal of General Physiology bit.ly/3IXrOSN

Excited to share our latest article in Scientific Reports with Aaron Russell that adrenal and vascular function, via a link with oestrogen, is associated with the unconditioned fear response in the mdx mouse model of #DMD. Click the link below to read more! rdcu.be/c89Xy

I'm reading this paper biorxiv.org/content/10.110… and my brain just keeps going 🤯. - Fear triggers switch from Glutamate to GABA🤯 - Driven by HPA axis 🤯 -

PhD Opportunity #Myotwitter If you are interested in the mechanisms regulating skeletal muscle adaptability then please apply to join my new lab University of Canterbury, Christchurch, New Zealand! tinyurl.com/SMUcP Scholarships are available for stipend + tuition fees. Please RT

Safety and efficacy of tamoxifen in boys with Duchenne muscular dystrophy (TAMDMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Neurology thelancet.com/journals/laneu…

EMA's CHMP issued a positive opinion in favor of the approval of AGAMREE® (vamorolone) for DMD patients aged 4 years and up. 🤝 The Duchenne community's contributions as funders, research participants, and our support as Vision-DMD Project partner were pivotal. worldduchenne.org/news/europe-ch…

Excited to release our new work linking clock regulated splicing factor Rbm20 to metabolic disruption in estrogen deprived mdx muscle: Loss of endogenous estrogen alters mitochondrial metabolism and muscle clock-related protein Rbm20 in female mdx mice biorxiv.org/content/10.110…

Potential limitations of micro-dystrophin gene therapy for Duchenne muscular dystrophy insight.jci.org/articles/view/…

Genethon's gene therapy trial has shown efficacy in treating Duchenne muscular dystrophy (DMD). Results show that 8 weeks after injection, up to 85% of muscle fibers expressed microdystrophin and there was a decrease in CPK levels. Find out more here: genethon.com/first-clinical…

Our paper has just been published in FASEB Journal! My first foray with omics data - massive learning curve but so worth it! Loss of endogenous estrogen alters mitochondrial metabolism and muscle clock‐related protein Rbm20 in female mdx mice - faseb.onlinelibrary.wiley.com/doi/10.1096/fj…

**Postdoc position** I have a fully funded postdoc position available in the Neurology of Myopathies Lab University of Canterbury for 2 years to design and test therapies for the muscular dystrophies. If you are interested in joining a vibrant lab in beautiful Christchurch, New Zealand, DM me!

I am thrilled that my lab’s new paper, “Systemic delivery of full-length dystrophin in Duchenne muscular dystrophy mice”, was just published at Nature Communications . This study describes a new gene therapy strategy to deliver full-length dystrophin for DMD. rdcu.be/dOt3d

Congratulations to Gretel Major and collaborators from Deakin IPAN, Macquarie University and University of Canterbury for our latest article highlighting cardio-metabolic and cytoskeletal proteomic signatures differentiate stress sensitivity in mdx mice sciencedirect.com/science/articl…

Fascinating bioRxiv on muscle and neuronal-specific conditional ablation of dystrophin - congrats Matthew S. Alexander and colleagues. biorxiv.org/content/10.110…